Tech Company Financing Transactions

Centivax Funding Round

On 3/25/2026, Centivax secured $37 million in funding from Structure Capital, private investors and Kendall Capital Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

329 Oyster Point Boulevard South
San Francisco, CA 94080
USA

Phone

Undisclosed

Website

www.centivax.com

Email Address

[email protected]

Overview

Developer of a therapeutics and clinical-stage company intended to treat and eradicate rapidly mutating pathogens. The company applies its computational immune engineering expertise to develop therapeutic monoclonal antibodies against a variety of targets, it builds a panel of neutralizing antibodies against SARS-CoV-2, enabling people to be safe from health issues with the help of vaccinations.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jacob Glanville

        

Chief Operating Officer

David Tsao

        

Chief Technical Officer

Nicholas Bayless

        

Co-Founder

Sawsan Youssef

        

Browse more venture capital transactions:

Prev: 3/25/2026: Cellbricks Therapeutics venture capital transaction
Next: 3/25/2026: Subbyx venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary